In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings from an overall survival (OS) analysis of the Phase III ZUMA-7 trial (NCT03391466), which is evaluating axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.